Baltimore City Reaches Significant Settlement with Purdue and Teva Pharmaceuticals
Baltimore Settles with Purdue Pharma and Teva Pharmaceuticals
Baltimore has reached a significant settlement of $80 million with Purdue Pharma and Teva Pharmaceuticals over claims related to the opioid crisis. This is the fourth settlement the city has initiated under the leadership of Mayor Brandon Scott, who continues to advocate for accountability among drug manufacturers. The aim is to reconcile the harms caused by opioid addiction with substantial financial restitution.
Impact of the Settlement
- Total Compensation: The $80 million settlement is a critical resource.
- Future Initiatives: The funding will contribute to rehabilitation and prevention programs.
- Purdue and Teva's Responsibility: Both companies face ongoing scrutiny and legal challenges related to their role in the opioid epidemic.
This settlement underscores the urgent need for effective and sustainable measures to address opioid misuse in Baltimore City.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.